Appeal No. 95-0371
Application 07/965,304
1. A method of treating an autoimmune disease, comprising administering an
effective amount of fludarabine-5'-monophosphate.
4. A method of preventing the symptoms of an autoimmune disease, comprising
administering an effective amount of fludarabine-5'-monophosphate.
7. A method of ameliorating the symptoms of autoimmune disease, comprising
administering an effective amount of fludarabine-5'-monophosphate.
10. A method of prophylactically treating an autoimmune disease, comprising
administering an effective amount of fludarabine-5'-monophosphate.
The references relied upon by the examiner are:
Eur. Pat. App. (Paulson) 0,066,918 Dec. 15, 1982
Priebe et al. (Priebe), 114 Chemical Abstracts, No. 74862b, page 33 (1991).
The three references discussed by this merits panel are:
Priebe et al. (Priebe), “Purine Nucleoside Modulation of Functions of Human
Lymphocytes”, 129 Cellular Immunology, No. 2, 321-328 (Sept. 1990).
Boldt et al. (Boldt), “Effects on Human Peripheral Lymphocytes of in Vivo Administration of
9-$-D-Arabinofuranosyl-2-fluoroadenine-5'-monophosphate (NSC 312887), a New Purine
Antimetabolite”, 44 Cancer Research, 4661-4666 (Oct. 1984).
Carrera, “Potent Toxicity of 2-Chlorodeoxyadenosine toward Human Monocytes
In Vitro and In Vivo”, 86 The Journal of Clinical Investigations, No. 5, 1480-1488
(Nov. 1990).
Claim 7 stands rejected under 35 U.S.C. § 101 as lacking patentable utility. Claims
1, 4 and 5 stand rejected under 35 U.S.C. § 112, first paragraph, as being non-enabled by
the specification. Claims 1 through 12 stand rejected under 35 U.S.C.
§ 102(b) as anticipated by the Chemical Abstracts citation of Priebe. Finally, claims
3
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 Next
Last modified: November 3, 2007